Akari Therapeutics Plc

Name: Akari Therapeutics Plc standardized financial statements, quarterly
Creator: Listed

AKTXNasdaqCIK 1541157HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$4.6m, Q2 FY2026

Net income−$4.8m, Q2 FY2026

Akari Therapeutics Plc, income statement, quarterly
Line item	Unit	period not labelled2023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$m	(0.3)	2.5	2.3	3.3	0.1	1.2	0.8	0.7	0.2	1.1	1.5	2.1
Selling, general and administrative	$m	2.8	2.6	3.7	2.2	1.7	3.0	2.7	2.5	2.0	2.1	2.2	2.5
Operating income	$m	(2.5)	(5.1)	(6.0)	(7.4)	(2.9)	(5.3)	(3.5)	(3.1)	(7.4)	(3.2)	(15.8)	(4.6)
Interest expense	$m	not reported	not reported	not reported	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1
Income tax	$m	not reported	not reported	0.0	not reported	not reported	not reported	0.0	0.0	(1.1)	0.1	(0.9)	0.0
Net income	$m	(2.9)	(4.1)	(5.6)	(7.6)	(2.9)	(3.8)	(3.7)	(1.9)	(6.4)	(5.3)	(14.5)	(4.8)
Diluted EPS	$ per share	0.00	not reported	0.00	0.00	0.00	not reported	0.00	0.00	0.00	not reported	0.00	0.00
Basic EPS	$ per share	0.00	not reported	0.00	0.00	0.00	not reported	0.00	0.00	0.00	not reported	0.00	0.00

Balance sheet

Cash and equivalents$7.7m, Q2 FY2026

Shareholders' equity$18.6m, Q2 FY2026

Akari Therapeutics Plc, balance sheet, quarterly
Line item	Unit	FY20232023-12-31	period not labelled2024-02-29	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	3.8	not reported	1.3	4.2	2.2	0.0	2.6	2.7	2.5	5.2	2.8	7.7
Current assets	$m	4.3	not reported	2.8	5.1	2.7	3.0	3.3	3.3	2.9	5.5	3.6	8.3
Total assets	$m	4.4	not reported	2.8	5.1	2.7	50.6	51.0	50.9	45.4	47.9	33.9	38.6
Current liabilities	$m	4.6	not reported	6.3	8.8	9.4	19.9	20.9	17.1	15.6	12.4	13.4	13.9
Total liabilities	$m	4.6	not reported	not reported	not reported	not reported	28.3	29.2	25.3	22.7	19.6	19.5	20.0
Short-term borrowings	$m	not reported	1.1	0.9	0.6	0.2	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	(0.2)	not reported	(3.6)	(3.7)	(6.7)	22.2	21.7	25.6	22.7	28.3	14.4	18.6

Cash flow

Operating cash flow−$3.1m, Q2 FY2026

Akari Therapeutics Plc, cash flow, quarterly
Line item	Unit	period not labelled2023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(2,449)	(4,409)	(4,044)	(4,894)	(1,490)	(2,124)	(2,150)	(3,256)	(2,121)	(3,041)	(2,488)	(3,109)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)143.32bn, Q2 FY2026

Akari Therapeutics Plc, shares, quarterly
Line item	Unit	Q1 FY20162016-03-31	period not labelled2023-03-31	period not labelled2023-06-30	period not labelled2023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	bn shares	1.2	7.6	10.1	10.1	13.5	18.8	24.4	54.6	62.9	65.3	119	143

Shares outstanding: 155.76bn at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.